These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 541858)

  • 21. [Relationship between antiplasmin capacity and concentration of alpha 2-plasmin inhibitor, alpha 2-macroglobulin, alpha 1-antitrypsin, antithrombin III or C1-inactivator in plasma of patients with transient ischemic attacks (author's transl)].
    Matsuda T; Seki T; Miura R; Ogawara M; Yokouchi M; Yamanouchi H
    Rinsho Byori; 1980 Mar; 28(3):261-4. PubMed ID: 6154815
    [No Abstract]   [Full Text] [Related]  

  • 22. Polyethylene glycol can be validly omitted from chromogenic peptide substrate assay for antithrombin III.
    Kolde HJ
    Clin Chem; 1986 Aug; 32(8):1554-6. PubMed ID: 3731451
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Clinical evaluations of antithrombin III activity in acute liver injuries (author's transl)].
    Iwabuchi S; Mizuguchi A; Okabe K
    Nihon Shokakibyo Gakkai Zasshi; 1980 Oct; 77(10):1667. PubMed ID: 7452954
    [No Abstract]   [Full Text] [Related]  

  • 24. Inhibition of thrombin by antithrombin III and heparin cofactor II in vivo.
    Liu L; Dewar L; Song Y; Kulczycky M; Blajchman MA; Fenton JW; Andrew M; Delorme M; Ginsberg J; Preissner KT
    Thromb Haemost; 1995 Mar; 73(3):405-12. PubMed ID: 7545318
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Round table on the use of chromogenic substrates in hemostasiologic diagnosis].
    Vogel G
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1982; 109(1):189-200. PubMed ID: 6177604
    [No Abstract]   [Full Text] [Related]  

  • 26. [Antithrombin III determination in horses. Reference values and acquired antithrombin III deficiency].
    Gerhards H
    Tierarztl Prax; 1987; 15(1):47-55. PubMed ID: 3590168
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Changes in antithrombin III values during and after extracorporeal circulation in heart surgery, measured on the day of operation using a chromogenic substrate and a laser nephelometer].
    Hopmeier P; Heuss F; Fischer M
    Wien Klin Wochenschr; 1984 Dec; 96(24):881-4. PubMed ID: 6528618
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Clinical significance of antithrombin III with special reference to diabetic retinopathy (author's transl)].
    Matsuo T; Ohoki Y; Kondo S
    Nihon Ronen Igakkai Zasshi; 1979 Nov; 16(6):551-5. PubMed ID: 119077
    [No Abstract]   [Full Text] [Related]  

  • 29. [Thrombin/antithrombin III complex (TAT)--a new parameter for detection of thrombotic states].
    Pelzer H
    Rinsho Byori; 1989 Apr; Spec No 81():198-201. PubMed ID: 2666687
    [No Abstract]   [Full Text] [Related]  

  • 30. [Biological monitoring of antithrombosis treatments (author's transl)].
    Samama M
    Ann Cardiol Angeiol (Paris); 1981 Dec; 30(7):483-6. PubMed ID: 7332257
    [No Abstract]   [Full Text] [Related]  

  • 31. Antithrombin-III: clinical significance.
    ten Cate JW
    Acta Chir Scand Suppl; 1982; 509():101-3. PubMed ID: 6962610
    [No Abstract]   [Full Text] [Related]  

  • 32. Antithrombin III assay using thrombin in disseminated intravascular coagulation (DIC), other thromboembolic disorders and hepatic diseases.
    Saxena V; Mishra DK; Subramanya H; Satyanarayana S; Sharma A
    Indian J Pathol Microbiol; 2004 Apr; 47(2):210-2. PubMed ID: 16295470
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Coagulation parameters in patients with hypertension].
    García E; Rodríguez M; Díez ML; Navarro A
    Rev Esp Fisiol; 1982; 38 Suppl():277-80. PubMed ID: 7146584
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Clinical problems of the natural coagulation and fibrinolysis inhibitors--central nervous system (author's transl)].
    Maruyama I
    Rinsho Ketsueki; 1978 Jul; 19(7):920-6. PubMed ID: 702827
    [No Abstract]   [Full Text] [Related]  

  • 35. [Diagnosis of increased thrombotic tendency with chromogenic substrates].
    Vinazzer H
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1982; 109(1):135-41. PubMed ID: 6177594
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Comparative studies on the determination of abnormal antithrombin III activity].
    Nagy I; Losonczy H
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1982; 109(1):180-3. PubMed ID: 6177602
    [No Abstract]   [Full Text] [Related]  

  • 37. Internalization of antithrombin III by cultured human endothelial cells and its subcellular localization.
    van Iwaarden F; Acton DS; Sixma JJ; Meijers JC; de Groot PG; Bouma BN
    J Lab Clin Med; 1989 Jun; 113(6):717-26. PubMed ID: 2659712
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Automation of antithrombin III methods on routinely available instruments.
    Conard J
    Semin Thromb Hemost; 1983 Oct; 9(4):263-7. PubMed ID: 6658460
    [No Abstract]   [Full Text] [Related]  

  • 39. A method for the determination of antithrombin III using a unique synthetic substrate.
    Reczek PR; Martel AS; Lorenzi-Anderson M; Hills L; Jensen MD
    Thromb Res; 1986 Feb; 41(3):431-6. PubMed ID: 3705016
    [No Abstract]   [Full Text] [Related]  

  • 40. False low antithrombin III results in renal disease.
    Fisher AH
    Med Lab Sci; 1985 Jan; 42(1):44-7. PubMed ID: 3982246
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.